Group A：Patients with PR or ctDNA positivity after salvage treatment
2024378
Phase 2 small_molecule active
Quick answer
Group A：Patients with PR or ctDNA positivity after salvage treatment for Diffuse Large B-cell Lymphoma(DLBCL) is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Diffuse Large B-cell Lymphoma(DLBCL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active